Previous close | 1.1400 |
Open | 1.1450 |
Bid | 1.1450 x 1161000 |
Ask | 1.1450 x 1753300 |
Day's range | 1.1400 - 1.1450 |
52-week range | 0.6250 - 1.1450 |
Volume | |
Avg. volume | 600,179 |
Market cap | 290.505M |
Beta (5Y monthly) | 1.68 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Volpara Health Technologies Ltd. (ASX: VHT), a global leader in software for the early detection and prevention of cancer, today debuted a new central, digital destination to manage mammography systems, staff credentials and professional development in support of compliance with the Food & Drug Administration's Mammography Quality Standards Act (MQSA). Volpara® Quiver™ software is featured at the Society for Breast Imaging's (SBI) annual symposium alongside the company's suite of solutions for a
Volpara Health Technologies Ltd. (ASX: VHT), a global leader in software for the early detection and prevention of cancer, will showcase its latest software advancements for breast centers at the 2024 National Consortium of Breast Centers (NCBC) conference, March 15-19 in Las Vegas. Volpara will feature Lunit's INSIGHT™ AI-software for early cancer detection alongside the company's suite of solutions for assessing breast density, evaluating cancer risk, and mammography quality.
Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced a significant update on its acquisition of Volpara Health Technologies (Volpara; ASX:VHT). An initial order from the High Court of New Zealand has been granted, and all necessary consents under New Zealand's Overseas Investment Act and Overseas Investment Regulations have been secured to facilitate the implementation of the Scheme. The initial order signals approval and mand